PRINCETON, N.J–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) today announced that 28 abstracts related to ORENCIA® (abatacept) and the Company’s immunoscience pipeline will be presented at the 2018 American College of Rheumatology and Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting, October 19-24, 2018, in Chicago. The abstracts accepted for presentation include clinical and …
Tag Archives: ACR
October, 2018
November, 2016
-
14 November
Celltrion Presents New Data Supporting Efficacy and Safety of its Biosimilars
WASHINGTON–(BUSINESS WIRE)–New data presented today at the 2016 American College of Rheumatology (ACR) Annual Meeting demonstrate that the efficacy and safety profile of CT-P10 (biosimilar rituximab) in rheumatoid arthritis (RA) patients is comparable to patients treated with originator rituximab over 24 weeks.1,2 A total of 372 RA patients (161 patients …
July, 2016
-
1 July
Rheumatology Providers, FDA Leaders Discuss Biosimilar Policy Challenges & Opportunities at National Policy Briefing
WASHINGTON, DC – Experts from the American College of Rheumatology (ACR), Food and Drug Administration (FDA), and other leading national healthcare groups spoke about the emerging biosimilars market, including key policy and regulatory questions for patients, providers and the healthcare system, during a national policy briefing held today by the …
March, 2016
-
31 March
Lilly Announces Positive Results from its Late-Stage Trial of its Rheumatoid Arthritis Drug
INDIANAPOLIS, March 31, 2016 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced that detailed results of RA-BEACON — a pivotal phase 3 global study of baricitinib, a once-daily oral treatment currently under regulatory review for the treatment of moderate-to-severe rheumatoid arthritis (RA) — were …
January, 2016
-
11 January
Baxalta and Coherus’ Enbrel Biosimilar Meets Primary Endpoint in Late-Stage Study
REDWOOD CITY, Calif., and BANNOCKBURN, Ill., Jan. 11, 2016 (GLOBE NEWSWIRE) — Coherus BioSciences, Inc. (NASDAQ:CHRS) and Baxalta Incorporated (NYSE:BXLT) today announced that CHS-0214, a proposed biosimilar of Enbrel® (etanercept), met its primary endpoint in a confirmatory, double-blind, randomized, controlled, two-part clinical study. This ongoing study is evaluating the efficacy and safety of CHS-0214 compared to Enbrel in patients …
April, 2015
-
21 April
Federal Panel Drafts Controversial Recommendations on Breast Cancer Screening
Debate surrounding the recommended age for women to initiate breast cancer screening has caused a stir between experts, and a draft proposal from the US Preventive Services Task Force (USPSTF) could potentially cause insurers to stop covering mammograms in younger individuals. On Monday, the USPSTF issued a draft proposal saying …